Page last updated: 2024-09-03

mk 0663 and diethylnitrosamine

mk 0663 has been researched along with diethylnitrosamine in 1 studies

Compound Research Comparison

Studies (mk 0663)	Trials (mk 0663)	Recent Studies (post-2010) (mk 0663)	Studies (diethylnitrosamine)	Trials (diethylnitrosamine)	Recent Studies (post-2010) (diethylnitrosamine)
549	173	265	3,614	1	888

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Abo-Youssef, A; Ahmed, O; Ali, G; Hersi, F; Mohamed, W; Omar, H	1

Other Studies

1 other study(ies) available for mk 0663 and diethylnitrosamine

Article	Year
The Protective Role of Etoricoxib Against Diethylnitrosamine/2-acetylaminofluorene- Induced Hepatocarcinogenesis in Wistar Rats: The Impact of NF-κB/COX-2/PGE2 Signaling. Current molecular pharmacology, 2022, Volume: 15, Issue:1 Topics: 2-Acetylaminofluorene; Animals; Carcinoma, Hepatocellular; Cyclooxygenase 2; Diethylnitrosamine; Dinoprostone; Etoricoxib; Female; Humans; Liver Neoplasms; Male; NF-kappa B; Rats; Rats, Wistar	2022

Article

Year

The Protective Role of Etoricoxib Against Diethylnitrosamine/2-acetylaminofluorene- Induced Hepatocarcinogenesis in Wistar Rats: The Impact of NF-κB/COX-2/PGE2 Signaling.

Current molecular pharmacology, 2022, Volume: 15, Issue:1

Topics: 2-Acetylaminofluorene; Animals; Carcinoma, Hepatocellular; Cyclooxygenase 2; Diethylnitrosamine; Dinoprostone; Etoricoxib; Female; Humans; Liver Neoplasms; Male; NF-kappa B; Rats; Rats, Wistar

2022